Clinical Trials
75 trialsNCT06006273 2026-05-20
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT05978492 2025-04-24
A Study of TXN10128 in Subjects With Solid Tumors
Txinno Bioscience Inc.
Phase 1 Recruiting
NCT04492033 2025-01-27
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
Phase 1/2 Terminated
NCT06760117 2025-01-06
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Sun Yat-sen University
Phase 1 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT05620862 2024-07-09
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
Sun Yat-sen University
Phase 1 Active not recruiting
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Unknown
NCT05148195 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00993044 2023-10-06
VIT-B
Children's Hospital Los Angeles
Phase 1 Completed
NCT02588105 2022-09-19
AToM
AstraZeneca
Phase 1 Completed
NCT02250157 2022-02-22
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT05177276 2022-01-04
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03318445 2021-03-04
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
University of California, San Francisco
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04689100 2020-12-30
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Shanghai JMT-Bio Inc.
Phase 1 Unknown
NCT02157792 2020-04-01
M6620 First in Human Study
EMD Serono
Phase 1 Completed
NCT02747537 2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
Phase 2 Withdrawn
NCT00002902 2019-03-13
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT00215501 2018-11-02
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03503604 2018-04-20
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Phase 1 Unknown
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT01593228 2017-09-19
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi
Phase 3 Completed
NCT00861328 2017-06-23
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Traws Pharma, Inc.
Phase 1 Completed
NCT00186979 2017-04-26
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00731276 2017-03-31
Irinotecan in Treating Asian Patients With Solid Tumors
National Cancer Centre, Singapore
Phase 1 Completed
NCT00026195 2016-07-06
Irinotecan in Treating Aging Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00547547 2015-11-06
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed
NCT02395068 2015-08-19
Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
Biotech Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00020488 2015-04-30
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01463982 2015-04-23
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT00008424 2014-05-05
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
Children's Oncology Group
Phase 1 Completed
NCT01141244 2014-04-10
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00046917 2014-02-24
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006095 2014-02-21
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
Children's Oncology Group
Phase 1 Completed
NCT00054288 2014-01-13
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00112892 2014-01-13
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00004051 2013-12-19
Irinotecan in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005791 2013-12-19
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00021073 2013-12-11
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002939 2013-09-05
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
University of Chicago
Phase 1 Completed
NCT00004919 2013-07-02
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed